Form 4 for LGND LIGAND PHARMACEUTICALS INC
Accepted 2023-07-10 00:00:00 ET · period of report 2023-06-30 · accession 0000886163-23-000044 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2023-07-10 | 2023-06-30 | LGND | Espinoza Octavio | CFO | J - Other | $56.78 | +375 | 24.5K | +2% | +$21.3K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2023-06-30 | J | A | 375 | $56.78 | 24,517 | D | — | — |